Summary
Mankind Pharma has entered an exclusive in-licensing agreement with China's Chongqing Chenan Biopharmaceutical to commercialize two insulin analogues for diabetes care. This partnership aims to strengthen Mankind Pharma's injectable diabetes segment and expand its patient portfolio.